Nanofluidic Drug-Eluting Seed for intratumoral drug delivery (NDES)
The nanofluidic drug-eluting seed (NDES) is a tiny intratumoral implant that uses a silicon nanofluidic membrane for sustained local drug delivery. By delivering therapeutics directly to the tumor, the NDES could improve treatment effectiveness and avoid exposing the body to harmful drug side effects. The NDES is drug- and tumor-agnostic and can be adopted as a drug-eluting radiopaque fiducial or for image-guided theranostic approaches. We have investigated local delivery of chemotherapy, immunotherapy, and imaging contrast agents in various murine cancer models. Current therapeutic focus entails intratumoral immunotherapy, based on the premise that local priming of the anti-tumor immune response can yield durable systemic immunity with minimal toxicity. Combination studies of intratumoral immunotherapy with radiotherapy are currently ongoing in various murine cancer models, including breast cancer and pancreatic cancer. Our innovation aims to change cancer treatment paradigm in a safer and more effective manner.
Reference: Liu, H.-C. et al. International Journal of Radiation Oncology*Biology*Physics 2020.